Active, not recruitingPhase 1NCT06652737

Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

Studying Malaria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sanaria Inc.
Principal Investigator
Thomas L Dr. Thomas L. Richie, MD PhD
Sanaria Inc.
Intervention
PfSPZ-LARC2 Vaccine(biological)
Enrollment
75 target
Eligibility
1-50 years · All sexes
Timeline
20252026

Study locations (1)

Collaborators

University of Maryland, Baltimore · Groupe de Recherche Action en Sante · Seattle Children's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06652737 on ClinicalTrials.gov

Other trials for Malaria

Additional recruiting or active studies for the same condition.

See all trials for Malaria

← Back to all trials